stockrowDare Bioscience, Inc.
DARE Healthcare Biotechnology
Dare Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, up 10,412.2% from fiscal 2024.
- Revenue
- +984.4%
- EPS
- +55.6%
- Free cash flow
- −30.2%
Quarter to June 2026, against a year earlier
Follow DARE
Alert me
Dare Bioscience, Inc. (DARE) EV/Sales
As of 6 November 2026, Dare Bioscience, Inc. (DARE) trades at a EV/Sales of 3.9×. Over the past ten years it has ranged from −1,736× (July 2025) to 2,167× (January 2025); the current reading is higher than 85% of that period. That is below the Biotechnology industry median of 9.0× and in line with the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.1× | (99.74%) |
| FY2024 | 1,942× | 94,073.59% |
| FY2023 | 2.1× | — |
| FY2022 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 19.9× | 41.42% |
| Mar 2026 | 14.1× | 177.40% |
| Dec 2025 | 5.1× | — |
| Sep 2025 | −211× | — |
| 9 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| GUTS Fractyl Health, Inc. compare | −51.6× |
| AEON AEON Biopharma, Inc. compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | n/m |
| CASIF CASI Pharmaceuticals Inc. compare | 1.8× |
| BOLT Bolt Biotherapeutics, Inc. compare | 2.5× |
| DARE Dare Bioscience, Inc. | 3.6× |
| BCDA BioCardia, Inc. compare | 29.3× |
| HIND Vyome Holdings, Inc. compare | 125× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)